Conjunctival Flap with Biodegradable Collagen Matrix Implantation for the Treatment of Scleromalacia after Periocular Surgery

Kyung Eun Han, Sangchul Yoon, Roo Min Jun, Tae-im Kim, Eungkweon Kim, KyoungYul Seo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To report a new surgical procedure using biodegradable collagen matrix (Ologen) implantation with conjunctival flap for reconstruction of scleromalacia after periocular surgery. Methods: A total of 26 areas of 25 eyes in 25 patients were included. We divided all eyes according to the preoperative extent of calcified plaque or scleral defect as follows: small, large, and large and severe. Morphologic outcomes were graded from 0 to 7, with higher scores indicating worse cosmetic outcomes. Results: Mean follow-up period was 8.3 ± 5.6 months. No eyes showed recurrence or specific complications related to Ologen such as implant extrusion or allergic reaction. Minor complications such as flap vessel engorgement and flap hypertrophy were easily treated. Mean morphologic outcome scores were 1.8, 2.4, and 5.3 in groups 1, 2, and 3, respectively. Discussion: The combined surgery may be an effective and safe procedure for the treatment of scleromalacia after periocular surgeries.

Original languageEnglish
Pages (from-to)614-621
Number of pages8
JournalOcular Immunology and Inflammation
Volume27
Issue number4
DOIs
Publication statusPublished - 2019 May 19

Fingerprint

Collagen
Cosmetics
Hypertrophy
Hypersensitivity
Therapeutics
Recurrence
collagen-glycosaminoglycan copolymer

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Ophthalmology

Cite this

@article{3c0194fb52e0400dbb2c2248246fee0c,
title = "Conjunctival Flap with Biodegradable Collagen Matrix Implantation for the Treatment of Scleromalacia after Periocular Surgery",
abstract = "Purpose: To report a new surgical procedure using biodegradable collagen matrix (Ologen) implantation with conjunctival flap for reconstruction of scleromalacia after periocular surgery. Methods: A total of 26 areas of 25 eyes in 25 patients were included. We divided all eyes according to the preoperative extent of calcified plaque or scleral defect as follows: small, large, and large and severe. Morphologic outcomes were graded from 0 to 7, with higher scores indicating worse cosmetic outcomes. Results: Mean follow-up period was 8.3 ± 5.6 months. No eyes showed recurrence or specific complications related to Ologen such as implant extrusion or allergic reaction. Minor complications such as flap vessel engorgement and flap hypertrophy were easily treated. Mean morphologic outcome scores were 1.8, 2.4, and 5.3 in groups 1, 2, and 3, respectively. Discussion: The combined surgery may be an effective and safe procedure for the treatment of scleromalacia after periocular surgeries.",
author = "Han, {Kyung Eun} and Sangchul Yoon and Jun, {Roo Min} and Tae-im Kim and Eungkweon Kim and KyoungYul Seo",
year = "2019",
month = "5",
day = "19",
doi = "10.1080/09273948.2018.1424340",
language = "English",
volume = "27",
pages = "614--621",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "4",

}

Conjunctival Flap with Biodegradable Collagen Matrix Implantation for the Treatment of Scleromalacia after Periocular Surgery. / Han, Kyung Eun; Yoon, Sangchul; Jun, Roo Min; Kim, Tae-im; Kim, Eungkweon; Seo, KyoungYul.

In: Ocular Immunology and Inflammation, Vol. 27, No. 4, 19.05.2019, p. 614-621.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Conjunctival Flap with Biodegradable Collagen Matrix Implantation for the Treatment of Scleromalacia after Periocular Surgery

AU - Han, Kyung Eun

AU - Yoon, Sangchul

AU - Jun, Roo Min

AU - Kim, Tae-im

AU - Kim, Eungkweon

AU - Seo, KyoungYul

PY - 2019/5/19

Y1 - 2019/5/19

N2 - Purpose: To report a new surgical procedure using biodegradable collagen matrix (Ologen) implantation with conjunctival flap for reconstruction of scleromalacia after periocular surgery. Methods: A total of 26 areas of 25 eyes in 25 patients were included. We divided all eyes according to the preoperative extent of calcified plaque or scleral defect as follows: small, large, and large and severe. Morphologic outcomes were graded from 0 to 7, with higher scores indicating worse cosmetic outcomes. Results: Mean follow-up period was 8.3 ± 5.6 months. No eyes showed recurrence or specific complications related to Ologen such as implant extrusion or allergic reaction. Minor complications such as flap vessel engorgement and flap hypertrophy were easily treated. Mean morphologic outcome scores were 1.8, 2.4, and 5.3 in groups 1, 2, and 3, respectively. Discussion: The combined surgery may be an effective and safe procedure for the treatment of scleromalacia after periocular surgeries.

AB - Purpose: To report a new surgical procedure using biodegradable collagen matrix (Ologen) implantation with conjunctival flap for reconstruction of scleromalacia after periocular surgery. Methods: A total of 26 areas of 25 eyes in 25 patients were included. We divided all eyes according to the preoperative extent of calcified plaque or scleral defect as follows: small, large, and large and severe. Morphologic outcomes were graded from 0 to 7, with higher scores indicating worse cosmetic outcomes. Results: Mean follow-up period was 8.3 ± 5.6 months. No eyes showed recurrence or specific complications related to Ologen such as implant extrusion or allergic reaction. Minor complications such as flap vessel engorgement and flap hypertrophy were easily treated. Mean morphologic outcome scores were 1.8, 2.4, and 5.3 in groups 1, 2, and 3, respectively. Discussion: The combined surgery may be an effective and safe procedure for the treatment of scleromalacia after periocular surgeries.

UR - http://www.scopus.com/inward/record.url?scp=85041530484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041530484&partnerID=8YFLogxK

U2 - 10.1080/09273948.2018.1424340

DO - 10.1080/09273948.2018.1424340

M3 - Article

C2 - 29420103

AN - SCOPUS:85041530484

VL - 27

SP - 614

EP - 621

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 4

ER -